Products
Lunsekimig Biosimilar Trispecific Antibody (IL-13 × TSLP × Albumin) for Research
Cat No.: GMP-Bios-INN-1272
Anti-IL13 therapeutic antibody (Pre-made Lunsekimig biosimilar,Trispecific and Pentavalent (sc-5-VH)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lunsekimig (development code SAR443765) is a trispecific antibody targeting IL-13, TSLP, and albumin. It is developed by Sanofi for asthma and inflammatory conditions. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1272-1mg | 1mg | |
| GMP-Bios-INN-1272-10mg | 10mg | |
| GMP-Bios-INN-1272-100mg | 100mg | |
| GMP-Bios-INN-1272-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lunsekimig biosimilar, Trispecific and Pentavalent (sc-5-VH), Anti-IL13;IL13;TSLP;ALB Antibody: Anti-IL-13/P600 therapeutic antibody |
| INN Name | Lunsekimig |
| Target | IL13;IL13;TSLP;ALB |
| Format | Trispecific and Pentavalent (sc-5-VH); Bispecific entry |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | na;na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Sanofi |
| Conditions Approved | na |
| Conditions Active | Asthma;Inflammation |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
